BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, Higasa S, Moriki T, Yagi H, Miyata T, Murata M; For TTP group of Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour, and Welfare Sciences Research Grants. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol 2017;106:3-15. [DOI: 10.1007/s12185-017-2264-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018;16:14. [PMID: 30008620 DOI: 10.1186/s12959-018-0168-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
2 Falter T, Herold S, Weyer-Elberich V, Scheiner C, Schmitt V, von Auer C, Messmer X, Wild P, Lackner KJ, Lämmle B, Scharrer I. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab. Thromb Haemost 2018;118:1743-51. [PMID: 30235478 DOI: 10.1055/s-0038-1668545] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Li XM, Mo XY, Huang GQ, Zhang FJ. Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: A single center experience. Am J Emerg Med 2021;46:556-9. [PMID: 33214018 DOI: 10.1016/j.ajem.2020.11.019] [Reference Citation Analysis]
4 Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 2020;112:764-72. [PMID: 32856231 DOI: 10.1007/s12185-020-02974-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yokomichi H, Tanaka-Taya K, Koshida R, Nakano T, Yasui Y, Mori M, Ando Y, Morino S, Okuno H, Satoh H, Arai S, Mochizuki M, Yamagata Z. Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case-control study. Int J Hematol 2020;112:105-14. [PMID: 32253664 DOI: 10.1007/s12185-020-02866-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Galstyan GM, Klebanova EE. [Diagnosis of thrombotic thrombocytopenic purpura]. Ter Arkh 2020;92:207-17. [PMID: 33720596 DOI: 10.26442/00403660.2020.12.200508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kong DQ, Yin J, Yu ZQ, Zhou SY, Li J, Han Y, Wang ZY, Ruan CG. [Thrombotic thrombocytopenic purpura complicated with acute erythropoiesis dysfunction: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2019;40:141-3. [PMID: 30831630 DOI: 10.3760/cma.j.issn.0253-2727.2019.02.009] [Reference Citation Analysis]
8 Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int 2018;115:327-34. [PMID: 29875054 DOI: 10.3238/arztebl.2018.0327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
9 Tripiciano C, Zangari P, Montanari M, Leone G, Massella L, Garaboldi L, Massoud M, Lancellotti S, Strocchio L, Manno EC, Palma P, Corsetti T, Luciani M. Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. Front Pediatr 2021;9:743206. [PMID: 34796152 DOI: 10.3389/fped.2021.743206] [Reference Citation Analysis]
10 Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail 2020;42:19-29. [PMID: 31858861 DOI: 10.1080/0886022X.2019.1702057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nishida T, Nakano K, Satoh M, Fukuyo S, Akashi K, Tanaka Y. A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. Mod Rheumatol Case Rep 2021:rxab025. [PMID: 34506625 DOI: 10.1093/mrcr/rxab025] [Reference Citation Analysis]
12 Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A; Nine-i Investigators. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med 2019;45:1518-39. [PMID: 31588978 DOI: 10.1007/s00134-019-05736-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
14 Oka S, Ono K, Nohgawa M. Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes. Int J Hematol 2020;111:771-8. [PMID: 32162096 DOI: 10.1007/s12185-020-02847-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Miesbach W, Menne J, Bommer M, Schönermarck U, Feldkamp T, Nitschke M, Westhoff TH, Seibert FS, Woitas R, Sousa R, Wolf M, Walzer S, Schwander B. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis 2019;14:260. [PMID: 31730475 DOI: 10.1186/s13023-019-1240-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
16 Yin J, Yu ZQ, Kong DQ, Wang ZY, Jin J, Wang J, Wang XM, Su J, Zhang W, Ruan CG. [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation]. Zhonghua Xue Ye Xue Za Zhi 2018;39:812-6. [PMID: 30369201 DOI: 10.3760/cma.j.issn.0253-2727.2018.10.005] [Reference Citation Analysis]
17 Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2486-95. [PMID: 32914582 DOI: 10.1111/jth.15006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
18 Matsumoto T, Toyoda H, Amano K, Hirayama M, Ishikawa E, Fujimoto M, Ito M, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Kawamura N, Ikejiri M, Kawakami K, Miyata T, Wada H. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. Clin Appl Thromb Hemost 2018;24:1301-7. [PMID: 29695177 DOI: 10.1177/1076029618771750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
19 Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Rev Hematol 2020;13:1153-64. [PMID: 32876503 DOI: 10.1080/17474086.2020.1819230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Romão de Souza V Jr, Beatriz Cavalcante de Oliveira A, Maria Vanderlei A, Queiroz da Mota Silveira Aroucha A, Pontes Duarte B, Nunes Machado A, Netto Chaer L, Wanderley de Barros Correia C, da Conceição de Barros Correia M, Freire Hazin Costa M. Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report. J Med Case Rep 2018;12:15. [PMID: 29357939 DOI: 10.1186/s13256-017-1545-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zickuhr L, Herlitz LC, Chatterjee S. A 22-Year-Old Woman With Systemic Lupus Erythematosus Presents With Two Damaged Kidneys, One Seizure, No Platelets, and Many Possible Diagnoses. Arthritis Care Res (Hoboken) 2018;70:1686-93. [PMID: 29579358 DOI: 10.1002/acr.23561] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hidalgo Filho CMT, Dalessandro Adamo DSM, Lopes CM, Martin EM. Thrombotic thrombocytopenic purpura associated with COVID-19 in a pediatric patient: case report. Hematol Transfus Cell Ther 2021. [PMID: 33846700 DOI: 10.1016/j.htct.2021.02.003] [Reference Citation Analysis]
23 Mackie I, Mancini I, Muia J, Kremer Hovinga J, Nair S, Machin S, Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hem 2020;42:685-96. [DOI: 10.1111/ijlh.13295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
24 Zhao T, Fan S, Sun L. The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome. BMC Genom Data 2021;22:50. [PMID: 34789164 DOI: 10.1186/s12863-021-01010-0] [Reference Citation Analysis]
25 Sakai K, Wada H, Nakatsuka Y, Kubo M, Hayakawa M, Matsumoto M. Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. J Intensive Care Med 2021;36:436-42. [PMID: 31964209 DOI: 10.1177/0885066619899637] [Reference Citation Analysis]
26 Okumura T, Hashimoto K, Aomura D, Kurasawa Y, Hara Y, Fujii K, Masuda T, Sonoda K, Yamaguchi A, Ogawa Y, Kamijo Y. Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism. Intern Med 2020;59:715-9. [PMID: 31708547 DOI: 10.2169/internalmedicine.3722-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Gui RY, Huang QS, Cai X, Wu J, Liu HX, Liu Y, Yang LH, Zhang JY, Cheng YF, Jiang M, Mao M, Fang MY, Liu H, Wang LR, Wang Z, Zhou HB, Lan H, Jiang ZX, Shen XL, Zhang L, Fan SJ, Li Y, Wang QF, Huang XJ, Zhang XH. Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. Br J Haematol 2020;191:269-81. [PMID: 32452543 DOI: 10.1111/bjh.16767] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Elverdi T, Özer Çerme MD, Aydın T, Eşkazan AE. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 2021;:1-6. [PMID: 34130583 DOI: 10.1080/17512433.2021.1944102] [Reference Citation Analysis]
29 Kayashima M, Sakai K, Harada K, Kanetake J, Kubo M, Hamada E, Hayakawa M, Hatakeyama K, Matsumoto M. Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Int J Hematol 2021;114:415-23. [PMID: 34292506 DOI: 10.1007/s12185-021-03197-5] [Reference Citation Analysis]
30 Han X, Li C, Zhang S, Hou X, Chen Z, Zhang J, Zhang Y, Sun J, Wang Y. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res 2020;196:500-9. [PMID: 33091704 DOI: 10.1016/j.thromres.2020.10.005] [Reference Citation Analysis]
31 Mariotte E, Zafrani L, Fadlallah J, Galicier L, Ghrenassia E, Kerhuel L, Calvet L, Jong A, Lemiale V, Valade S, Joly BS, Stepanian A, Azoulay E, Darmon M. Performance of Diagnostic Scores in Thrombotic Microangiopathy Patients in the Intensive Care Unit: A Monocentric Study. Thromb Haemost 2021. [PMID: 33512705 DOI: 10.1055/a-1378-3804] [Reference Citation Analysis]
32 Galstyan GM, Maschan AA, Klebanova EE, Kalinina II. Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 2021;93:736-45. [DOI: 10.26442/00403660.2021.06.200894] [Reference Citation Analysis]
33 Raval JS, Rollins-Raval MA, Mazepa MA, Park YA. Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass? J Clin Apher 2020;35:236-7. [PMID: 32449953 DOI: 10.1002/jca.21777] [Reference Citation Analysis]
34 Yue C, Su J, Fan X, Song L, Jiang W, Xia J, Shi T, Zhang X, Li X. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study. Orphanet J Rare Dis 2020;15:225. [PMID: 32859237 DOI: 10.1186/s13023-020-01510-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wada H, Shiraki K, Matsumoto T, Shimpo H, Yamashita Y, Shimaoka M. The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100012. [DOI: 10.1016/j.tru.2020.100012] [Reference Citation Analysis]
36 Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol 2021;194:444-52. [PMID: 34046888 DOI: 10.1111/bjh.17560] [Reference Citation Analysis]
37 Yoshida K, Murata S, Morimoto M, Mushino T, Tanaka K, Yamashita Y, Hosoi H, Nishikawa A, Tamura S, Hatakeyama K, Matsumoto M, Sonoki T. Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report. Hematology Reports 2022;14:203-9. [DOI: 10.3390/hematolrep14020027] [Reference Citation Analysis]
38 Uchino K, Sakai K, Shinohara S, Matsuhisa A, Iida Y, Nakano Y, Matsumura S, Kanasugi J, Takasugi S, Nakamura A, Horio T, Murakami S, Mizuno S, Yamamoto H, Hanamura I, Matsumoto M, Takami A. Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature. Int J Hematol 2022. [PMID: 35274194 DOI: 10.1007/s12185-022-03319-7] [Reference Citation Analysis]
39 Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2503-12. [PMID: 32914535 DOI: 10.1111/jth.15009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
40 Kovarova P, Hrdlickova R, Blahutova S, Cermakova Z. ADAMTS13 kinetics after therapeutic plasma exchange and plasma infusion in patients with Upshaw-Schulman syndrome. J Clin Apher 2019;34:13-20. [DOI: 10.1002/jca.21664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
41 Sakai K, Kuwana M, Tanaka H, Hosomichi K, Hasegawa A, Uyama H, Nishio K, Omae T, Hishizawa M, Matsui M, Iwato K, Okamoto A, Okuhiro K, Yamashita Y, Itoh M, Kumekawa H, Takezako N, Kawano N, Matsukawa T, Sano H, Ohshiro K, Hayashi K, Ueda Y, Mushino T, Ogawa Y, Yamada Y, Murata M, Matsumoto M. HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood 2020;135:2413-9. [DOI: 10.1182/blood.2020005395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
42 Song JC, Liu SY, Zhu F, Wen AQ, Ma LH, Li WQ, Wu J; Critical Care Medicine Committee of Chinese People’s Liberation Army (PLA); Chinese Society of Laboratory Medicine, Chinese Medical Association. Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China. Mil Med Res 2020;7:15. [PMID: 32241296 DOI: 10.1186/s40779-020-00244-w] [Reference Citation Analysis]